Article

Device facilitates safe cataract surgery

Chicago—Insertion of the Perfect Pupil Injectable (PPI, Milvella Pty. Ltd.) is an effective method for protecting the iris and maintaining a large pupil during cataract surgery in eyes predisposed to intraoperative floppy iris syndrome (IFIS), according to the results of an interventional case series reported at the annual meeting of the American Academy of Ophthalmology.

Chicago-Insertion of the Perfect Pupil Injectable (PPI, Milvella Pty. Ltd.) is an effective method for protecting the iris and maintaining a large pupil during cataract surgery in eyes predisposed to intraoperative floppy iris syndrome (IFIS), according to the results of an interventional case series reported at the annual meeting of the American Academy of Ophthalmology.

Dr. Milverton developed the PPI, is director of Milvella Pty. Ltd., and was the senior author of this study, which was performed at the Intraocular Implant Unit, Sydney Eye Hospital, Sydney, Australia. His co-author, Suresh K. Pandey, MD, Sydney Eye Hospital, reported the results at the annual meeting of the American Academy of Ophthalmology.

Results from the fellow eyes showed viscomydriasis with Healon 5 was effective for enlarging the pupil to a diameter of about 6.0 mm. However, progressive intraoperative miosis occurred during a phaco chop procedure, which was performed using high vacuum and flow rate parameters. A posterior capsule tear with vitreous loss occurred in one of the six eyes (17%). The visual outcomes at 3 months showed two eyes achieved 20/20 BCVA, three eyes were 20/30, and one had BCVA of 20/40.

Challenges with viscomydriasis

"When using Healon 5, the pupil may begin to constrict intraoperatively due to premature evacuation of the viscoelastic. Therefore, it is recommended that this method of viscomydriasis be used with a low aspiration flow rate and low vacuum and perhaps by surgeons accustomed to operating with those settings," Dr. Pandey said.

The patients included in the study were all older males (65 to 81 years) being treated with tamsulosin for benign prostatic hyperplasia. They had all discontinued tamsulosin treatment 3 weeks prior to their first eye surgery and presented with variable degrees of IFIS during the procedure.

The six men were identified over a 6-month period during which a total of 300 consecutive patients were prospectively screened for tamsulosin intake.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
© 2025 MJH Life Sciences

All rights reserved.